Regenxbio(RGNX) Stock Price Today | Quotes & News

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

RGNX Regenxbio

Watchlist

8.210
-0.490-5.63%

Close Mar 25 16:00 ET

8.200
-0.010-0.12%

Post 19:34 ET

411.21MMarket Cap-1.79P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

RegenXBio Positioned Favorably Amid Competitor Safety Concerns, Justifying Buy Rating
TipRanksMar 21 03:06 ET · Ratings
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $34
Moomoo NewsMar 21 02:31 ET · Ratings
Optimistic Buy Rating for RegenXBio Driven by Promising RGX-202 Developments in DMD Treatment
TipRanksMar 20 11:05 ET · Ratings
Analysts Are Neutral on These Healthcare Stocks: Medtronic (MDT), RegenXBio (RGNX)
TipRanksMar 20 09:10 ET · Ratings
Regenxbio's DMD Gene Therapy Drives 122.3% Biomarker Uptick in Three-year-old
Yahoo FinanceMar 20 07:53 ET
REGENXBIO Price Target Maintained With a $52.00/Share by Chardan Capital
Dow JonesMar 20 07:24 ET · Ratings

Comments

Lnova

Mar 19 10:31

$Regenxbio (RGNX.US)$
Phase 1/2 new biomarker data to be presented on 03/19/2025
*nfa

Teddy123

Mar 14 13:43

REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates

$Regenxbio (RGNX.US)$
REGENXBIO Advances Gene Therapy Pipeline with FDA Filing, Lands Massive $810M Partnership Deal

Jaguar8

Jan 15 11:45

🔴 Watchlist JANUARY 15,2025, Wednesday. NFA. I won’t be around tomorrow morning.

NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If yo...

Jaguar8

Jan 14 19:47

NEWS

$Regenxbio (RGNX.US)$
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
Tuesday, 14th January at 5:00 am
• REGENXBIO to receive $110 million upfront, potential milestone payments of up to $700 million and meaningful double-digit royalties on net sales, and lead manufacturing
• Nippon Shinyaku to lead commercialization of first potential gene therapies for Mucopolysaccharidosis II (MPS II) and Mucopolysaccharidosis ...

RGNX Regenxbio

Trade Overview

Capital Trend

News

Comments

Market Insights